Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.

ABSTRACT: Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to surgical intervention. The rationale is that shrinking a tumor will improve surgical outcomes and minimize growth of occult micrometastatic disease-thus delaying post-surgical recurrence and improving survival. But approved VEGF pathway inhibitors have not been tested in clinically relevant neoadjuvant models that compare pre- and post-surgical treatment effects. Using mouse models of breast, kidney, and melanoma metastasis, we demonstrate that primary tumor responses to neoadjuvant VEGFR TKI treatment do not consistently correlate with improved post-surgical survival, with survival worsened in certain settin

SUBMITTER: Ebos JM 

PROVIDER: S-EPMC4287975 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature